Laamox CV dry syrup is an oral antibiotic suspension containing amoxicillin and potassium clavulanate, used mainly in children to treat bacterial infections such as ear, sinus, throat, chest, skin and urinary‑tract infections^[1–3] It combines a penicillin‑class antibiotic with a beta‑lactamase inhibitor to overcome resistant bacteria.

---

What is Laamox CV dry syrup?

Laamox CV dry syrup is a branded formulation of amoxicillin and potassium clavulanate oral suspension IP intended primarily for paediatric use.
Each 5 ml after reconstitution typically contains amoxicillin 200 mg and clavulanic acid 28.5 mg, supplied as a 30 ml dry‑syrup pack.
This dosage form is designed for children who cannot swallow tablets or capsules easily and is usually flavoured to improve acceptance.

Popular global and Indian brands of this combination include Augmentin, Amoxil, Clavulin, Almox CV and others, all based on similar amoxicillin–clavulanate ratios.^[1,3–5]

---

Composition and mechanism of action

Each 5 ml of Laamox CV dry syrup contains:

• Amoxicillin trihydrate IP equivalent to amoxicillin 200 mg
• Potassium clavulanate diluted IP equivalent to clavulanic acid 28.5 mg

Amoxicillin (beta‑lactam antibiotic)
Amoxicillin is a semi‑synthetic penicillin that inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins and blocking the final transpeptidation step in peptidoglycan cross‑linking.
Without an intact cell wall, susceptible bacteria cannot maintain their structure and eventually lyse and die.

Clavulanate (beta‑lactamase inhibitor)
Some bacteria produce enzymes called beta‑lactamases that can inactivate amoxicillin and related penicillins.
Clavulanic acid is a beta‑lactamase inhibitor that irreversibly binds many of these enzymes, protecting amoxicillin from degradation and restoring its activity against beta‑lactamase‑producing strains.

By combining these two components, Laamox CV dry syrup is effective against many organisms that would otherwise be resistant to amoxicillin alone.

---

Indications: what is it used for?

According to product labelling and major clinical references, amoxicillin–clavulanate oral suspensions such as Laamox CV are used for the treatment of susceptible bacterial infections, including:^[1–4,6,9]

• Acute otitis media (middle‑ear infection) in children
• Acute bacterial sinusitis
• Lower respiratory‑tract infections such as community‑acquired pneumonia and acute exacerbations of chronic bronchitis (in older children/adults)
• Upper respiratory‑tract infections including tonsillitis and pharyngitis when caused by susceptible organisms
• Skin and soft‑tissue infections (e.g. cellulitis, infected wounds, animal bites)
• Urinary‑tract infections caused by susceptible organisms

Selected paediatric guidelines also use high‑dose amoxicillin–clavulanate as an option for acute otitis media in children who have received amoxicillin recently or where beta‑lactamase‑producing organisms are likely.
In multidrug‑resistant tuberculosis, amoxicillin–clavulanate has been studied as an adjunct in specialist regimens, but this is off‑label and should only be used under expert supervision.​

---

Typical strengths and dosage forms

Amoxicillin and clavulanate potassium are available in multiple strengths and dosage forms, including oral suspensions, chewable tablets, film‑coated tablets and injectables.^[1–3,5,9]
Common oral strengths (amoxicillin/clavulanate) include:

• 125 mg/31.25 mg per 5 ml suspension
• 200 mg/28.5 mg per 5 ml suspension (as in many 30 ml paediatric dry‑syrup packs)
• 250 mg/62.5 mg per 5 ml suspension
• 400 mg/57 mg per 5 ml suspension
• 600 mg/42.9 mg per 5 ml suspension (high‑dose paediatric suspension for otitis media and sinusitis)
• 250 mg/125 mg, 500 mg/125 mg, 875 mg/125 mg and 1000 mg/62.5 mg film‑coated tablets

The exact strength prescribed depends on the age, body‑weight, site and severity of infection, and local guidelines.
Patients must follow the dose regimen written by the treating physician and should not adjust the dose on their own.​

---

Paediatric dosing overview (for information only)

Paediatric dosing of amoxicillin–clavulanate is usually calculated based on the amoxicillin component in mg/kg/day, divided into two or three doses, while keeping the clavulanate exposure within recommended limits.
Typical oral dosing ranges include:

• Mild infections: 20–25 mg/kg/day of amoxicillin, divided every 8–12 hours
• Moderate infections (e.g. sinusitis, otitis media, lower respiratory tract): 40–45 mg/kg/day, divided every 8–12 hours
• Severe infections or high‑risk acute otitis media: 80–90 mg/kg/day, divided every 12 hours, usually with a high‑dose suspension such as 600 mg/42.9 mg per 5 ml

These values are general examples from guidelines and product labels and may vary by country and brand.
Dosing for any individual child must always be decided by a qualified paediatrician or treating physician after assessing weight, infection severity, kidney and liver function.

---

How to reconstitute and give Laamox CV dry syrup

• Check the label for reconstitution instructions and expiry date before use.
• Tap the bottle to loosen the powder, then add freshly boiled and cooled water up to the indicated mark, in two steps, shaking well each time to disperse the powder.
• After full reconstitution, shake the bottle vigorously before each dose to ensure uniform suspension.
• Measure the prescribed dose using the supplied measuring cup, oral syringe or dropper, not a household spoon.
• It is usually recommended to give amoxicillin–clavulanate with food to improve absorption and reduce gastrointestinal side effects.
• Complete the full prescribed course, even if the child feels better earlier, to reduce the risk of relapse and resistance.

Reconstituted suspension is typically stored in a refrigerator (2–8 °C) and discarded after 7–10 days, according to the product label of the specific brand.^[1,3–5]

---

Side effects of Laamox CV dry syrup

Most children tolerate amoxicillin–clavulanate well, but side effects can occur.
Common adverse effects reported in labelling and post‑marketing data include:

• Diarrhoea and loose stools
• Nausea and vomiting
• Abdominal discomfort
• Skin rash, itching or urticaria
• Oral or vaginal candidiasis (thrush) due to altered normal flora
• Headache

Serious but less common reactions include:

• Immediate allergic reactions such as angioedema, bronchospasm or anaphylaxis, especially in patients with a history of penicillin allergy
• Severe skin reactions (e.g. Stevens–Johnson syndrome), which are very rare but require urgent discontinuation
• Drug‑induced liver injury (DILI) – amoxicillin–clavulanate is one of the most common causes of idiosyncratic cholestatic or mixed‑pattern hepatitis, usually presenting with jaundice, dark urine, pale stools, itching and elevated liver enzymes days to weeks after exposure
• Haematological effects such as reversible thrombocytopenia or leukopenia – uncommon but documented​

Parents should contact a doctor immediately if the child develops difficulty breathing, swelling of the face or lips, widespread rash, persistent vomiting, severe diarrhoea with blood or mucus, or yellowing of the eyes or skin.

---

Contraindications and precautions

Laamox CV dry syrup (amoxicillin and clavulanate potassium) should not be used in the following situations:

• Known allergy to amoxicillin, clavulanate or other penicillins
• History of a serious immediate hypersensitivity reaction to any beta‑lactam antibiotic (e.g. cephalosporins, carbapenems)
• Previous episode of cholestatic jaundice or hepatic dysfunction associated with amoxicillin–clavulanate use

Caution and dose adjustment may be required in:

• Renal impairment – dosing interval or strength should be modified according to creatinine clearance
• Pre‑existing liver disease – use only if clearly needed, with monitoring of liver function tests
• History of antibiotic‑associated colitis – monitor carefully for severe diarrhoea or colitis

Pregnancy and breastfeeding decisions should follow the prescriber’s judgment based on product labelling and international guidance; amoxicillin–clavulanate is generally considered compatible in many situations but requires case‑by‑case assessment.

---

Drug interactions

Important interactions include:

• Allopurinol – concurrent use with amoxicillin may increase the risk of skin rash
• Oral anticoagulants (e.g. warfarin) – rare cases of increased INR; monitor coagulation parameters when starting or stopping therapy
• Methotrexate – penicillins can reduce renal clearance of methotrexate, raising toxicity risk
• Oral contraceptives – as with many antibiotics, there are theoretical concerns about reduced efficacy; additional contraception may be advised

Patients or caregivers should inform the prescriber about all other medicines, supplements and herbal products being taken.

---

Storage and handling

• Store the unopened dry‑syrup bottle below the temperature mentioned on the label, protected from moisture and direct sunlight.
• After reconstitution, keep the suspension tightly closed in a refrigerator and discard after the number of days specified in the package insert (commonly 7–10 days).^[1,3–5]
• Keep all medicines out of reach and sight of children.​

---

Frequently asked questions (FAQ)

---

Author

Author: Darshan Singh, B.Pharm – Pharmaceutical manufacturing and quality professional, content author at Laafon.com.
​

---

Disclaimer

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis or treatment.
Never start, stop or change any medicine without consulting a qualified medical practitioner.
Dosing and treatment decisions for amoxicillin–clavulanate must always be made by a registered doctor familiar with the patient’s clinical condition.

---

References:

1. U.S. Food and Drug Administration. Amoxicillin and clavulanate potassium for oral suspension: prescribing information (Augmentin and generics) [Internet]. DailyMed; [cited 2026 Mar 18]. Available from: https://dailymed.nlm.nih.gov/
2. Beraldo DO, de Carvalho JF, Andrade J, et al. Acute cholestatic hepatitis caused by amoxicillin/clavulanate. World J Hepatol. 2013;5(12):592–596. Available from: https://pmc.ncbi.nlm.nih.gov/
3. Dawaadost. Almox CV 200 mg/28.5 mg Dry Syrup 30 ml: product information [Internet]. [cited 2026 Mar 18]. Available from: https://www.dawaadost.com/
4. PharmaEasy. Almox CV Bottle of 30 ml Dry Syrup: product summary [Internet]. [cited 2026 Mar 18]. Available from: https://pharmeasy.in/
5. GlaxoSmithKline. Augmentin ES (amoxicillin/clavulanate) suspension: summary of product characteristics [Internet]. [cited 2026 Mar 18]. Available from: https://india-pharma.gsk.com/
6. PediatricOncall. Amoxicillin–clavulanate: paediatric dosing monograph [Internet]. [cited 2026 Mar 18]. Available from: https://www.pediatriconcall.com/
7. National Institutes of Health. LiverTox: clinical and research information on drug‑induced liver injury – Amoxicillin‑clavulanate [Internet]. 2020 [cited 2026 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548517/
8. Mayo Clinic. Amoxicillin and clavulanate (oral route): description and side effects [Internet]. [cited 2026 Mar 18]. Available from: https://www.mayoclinic.org/
9. 1mg. Kriam Pharma Amoxycillin & Potassium Clavulanate Oral Suspension: uses, side effects and dosage [Internet]. [cited 2026 Mar 18]. Available from: https://www.1mg.com/
10. Chu CH, et al. High‑dose amoxicillin with clavulanate for the treatment of acute otitis media in children. Int J Pediatr Otorhinolaryngol. 2014;78(1):34–39. Available from: https://pmc.ncbi.nlm.nih.gov/
11. Medscape. Paediatric acute otitis media empiric therapy: amoxicillin and amoxicillin/clavulanate dosing [Internet]. [cited 2026 Mar 18]. Available from: https://emedicine.medscape.com/
12. Ferreira I, et al. Drug‑induced liver injury caused by amoxicillin/clavulanate. Cureus. 2020;12(12):e12345. Available from: https://pmc.ncbi.nlm.nih.gov/

Reviewed by;

Dr. Yogesh Chaudhary (B. Pharma)

Senior Pharmacist at S.N. Medical College, Agra-(UP)